Thesis (M. P. H.)--University of Hong Kong, 2006. / Also available in print.

Thesis (Ph. D.)--Virginia Commonwealth University, 2007. / Prepared for: Dept. of Psychology. Bibliography: leaves 188-213. Also available online via the Internet.

Thesis (M.A.)--University of Texas at El Paso, 2009. / Title from title screen. Vita. CD-ROM. Includes bibliographical references. Also available online.

Thesis (M. Med. Sc.)--University of Hong Kong, 2005.

Thesis (Ph. D.)--University of California, San Diego and San Diego State University, 2010. / Available via ProQuest Digital Dissertations. Vita. Includes bibliographical references (leaves 69-80).

Thesis (M.P.H.)--University of Hong Kong, 2006.

Thesis (M. Nurs.)--University of Hong Kong, 2006.

Class of 2008 Abstract / Objectives: The purpose of this study is to determine the usefulness of expanded pharmaceutical care services and pharmacist involvement in smoking cessation for patients in a community setting, to identify demographical parameters for the population which might benefit the most from pharmacist intervention, and to examine the cost benefit of such intervention. Methods: This descriptive retrospective study was conducted through a MEDLINE search for all available literature regarding the efficacy of pharmacists in a community setting and smoking cessation outcomes. The results from these studies were then analyzed in order to identify demographic factors which may be associated with higher rates of positive outcome, and the potential cost benefit of such intervention. Information examined from the various articles included: type of study, method of data anaylsis, study/intervention location, patient age, sex, race, other comorbid conditions, and success rates including p values/odds ratios when stated. Results: After the original search, 63 publications were found using MEDLINE, including 12 systematic reviews and 3 clinical trials. After filtering, a total of 28 articles were analzyed. No correlations between demographic factors and successful smoking abstinence were found. All publications, save one, found a positive correlation between higher levels of intervention and increased smoking abstinence rates. Cost effectiveness varied depending on which method of NRT was utilized, ranging from $720 to $2360 per QALY saved. Several national health organizations have published guidelines stating the role of the pharmacist as essential in smoking cessation. Conclusions: Pharmacists have begun to play an essential role in smoking cessation, as evidenced by many successful ventures that have taken place to date. Still, there is vast potential for expansion of pharmaceutical care services in this area.

The present study examined various psychosocial variables that may influence success in a stop smoking program (QuitSmart) used by the North Texas Veterans Health Care Service (NTVHCS). The QuitSmart program utilizes the Stages of Change Model, with its focus on the last three stages (preparation, action, and maintenance). It was proposed that factors including shame-proneness, guilt, anger/hostility, depression, self-efficacy - both global and smoking situational, neuroticism, and level of nicotine dependence might individually or in combination predict attrition from the NTVHCS smoking cessation program. Results indicate that shame-proneness, guilt, anger/hostility, and depression did not individually predict attrition. Persons with high levels of smoking situational self-efficacy tend to utilize self-change strategies leading to greater success in smoking cessation. Participants with a psychological diagnosis, when combined with neuroticism and shame-proneness, appear to have more difficulty with cessation than those with only a medical diagnosis. Clinical implications and suggestions for change to the NTVHCS smoking cessation program are discussed.

BACKGROUND: We wanted to determine whether an intervention to enhance partner support helps as an adjunct to a smoking cessation program. METHODS: We undertook a meta-analysis of English-language, randomized controlled trials of smoking cessation interventions through July 2002 using the following data sources: Cochrane Tobacco Addiction Group specialized register, Cochrane controlled trials register, CDC Tobacco Information and Prevention Database, MEDLINE, Cancer Lit, EMBASE, CINAHL, PsycINFO, ERIC, PsycLIT, Dissertation Abstracts, SSCI and HealthSTAR, with reviews of bibliographies of included articles. Included were trials that assessed a partner support component with a minimum follow-up of 6 months. The outcomes measured were abstinence and biochemical assessment at 6 to 9 months and more than 12 months after treatment. Partner Interaction Questionnaire scores were primary and secondary outcomes. RESULTS: Nine studies (31 articles) met inclusion criteria. Partner definition varied among studies. All studies included self-reported smoking cessation rates, but there was limited biochemical validation of abstinence. For self-reported abstinence at 6 to 9 months after treatment, the Peto odds ratio (OR) = 1.08 (95% confidence interval [CI], 0.81-1.44) and at 12 months Peto OR = 1.0 (95% CI, 0.75-1.34). Sensitivity analysis of studies using live-in, married, and equivalent-to-married partners found a higher odds ratio at 6 to 9 months after treatment, Peto OR = 1.64 (95% CI, 0.5-4.64). Sensitivity analysis of studies reporting significant increases in partner support found at 6 to 9 months after treatment Peto OR = 1.83 (95% CI, 0.9-3.47); and at 12 months Peto OR = 1.22 (95% CI, 0.67-2.23). CONCLUSIONS: Interventions to enhance partner support showed the most promise for clinical practice when implemented with live-in, married, and equivalent-to-married partners. Such interventions should focus on enhancing supportive behaviors, while minimizing behaviors critical of smoking.